-- Earnings Flash (VBIV) VBI VACCINES Posts Q2 Revenue $346,000
8:01AM ET 8/08/2022 MT Newswires...
Quotes Snapshot > VBIV
VBI Vaccines Inc VBIV:NASDAQ
Last Price$1.22NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change0(0.00%)
Bid (Size)$1.22 (39)
Ask (Size)$1.23 (1,901)
Day Low / HighN/A - N/A
Volume1.6 M
Read more news Recent News
VBI Vaccines Receives FDA Orphan Drug Designation for Glioblastoma Treatment
8:17AM ET 6/22/2022 MT NewswiresVBI Vaccines (VBIV) said Wednesday it has received orphan drug designation from the US Food and Drug Administration for VBI-1901, which is intended for the...
VBI Vaccines Says Vaccine Candidate for Brain Tumors Shows Survival Benefit in Expanded Trial Data
1:48PM ET 6/06/2022 MT NewswiresVBI Vaccines (VBIV) said Monday updated tumor response and overall survival data from a phase 2a trial of VBI-1901 cancer vaccine candidate for recurrent...
VBI Says UK Healthcare Regulator Grants Marketing Approval for Hepatitis B Vaccine
11:16AM ET 6/01/2022 MT NewswiresVBI Vaccines (VBIV) said Wednesday it has secured marketing approval by the UK Medicines and Healthcare Products Regulatory Agency for its hepatitis B...
View all Commentary and Analysis
VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
9:21AM ET 6/17/2022 Seeking AlphaHookipa: Speculative Biotech With Key Catalysts In 2022
9:02AM ET 3/29/2022 Seeking AlphaVBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation
11:37AM ET 10/31/2021 Seeking AlphaCompany Profile
Business DescriptionVBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 160 2nd Street Cambridge, Massachusetts 02142 |
| Phone | +1.617.830.3031 |
| Number of Employees | 112 |
| President, Chief Executive Officer & Director | Jeff Baxter |
| CFO, Director & Head-Business Development | Christopher McNulty |
| Chief Medical Officer | Francisco Diaz-Mitoma |
| Chief Scientific Officer | David Evander Anderson |
Company Highlights
| Price Open | $1.13 |
| Previous Close | $1.10 |
| 52 Week Range | $0.64 - 3.81 |
| Market Capitalization | $315.1 M |
| Shares Outstanding | 258.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/14/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.39 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.4 M |
| Net Profit Margin | -15,391.36% |
| Return on Equity | -75.37% |
Analyst Ratings as of 06/10/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |